A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma


NCT Number:



Study Status:

Closed to Accrual, Study Active





The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the bloodstream, with the aim of helping them to attack and kill cancer cells. It is hoped to learn if these genetically changed T cells are safe and work to kill these cancer cell types.

Are you Eligible? (Inclusion Criteria)

  • Are you between the ages of 16 to 75?
  • Are you diagnosed with advanced (metastatic or inoperable) synovial sarcoma or myxoid liposarcoma / myxoid round cell liposarcoma?
  • Have you previously received either an anthracycline or ifosfamide containing treatment, or if you are intolerant to both anthracycline or ifosfamide, received at least one systemic therapy?

Specialty Area(s)

Sarcomas (Bone and Soft Tissue), Soft Tissue Sarcoma, Immunotherapy

Principal Investigator

Profile Headshot
  • Division Chief, Hematology/Oncology
  • Deputy Director, Herbert Irving Comprehensive Cancer Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032